Highlights

  • The HARNESS-1 Phase 1 clinical trial enrolled its first patient in March 2026, assessing RC220 (E,E-bisantrene) in combination with osimertinib in EGFR-mutated non-small cell lung cancer — a significant clinical milestone for the company's lung cancer program.
  • Racura's cash and cash equivalents totalled $19.38 million at 31 March 2026, with the company stating this is sufficient to fund all committed activities through CY2027 — removing near-term dilution risk as a share price overhang.
  • The company presented at the 2026 American Association of Cancer Research (AACR) Annual Meeting, disclosing preclinical results showing bisantrene silences MYC gene expression — a mechanistic finding with broad significance across multiple cancer types.

Racura Oncology Limited (ASX:RAC) has delivered one of the more striking share price performances on the ASX over the past year, with the stock up 98.52% over twelve months to trade at $2.68 on 13 May 2026. For a clinical-stage oncology company with no Revenue and a research-stage product portfolio, this kind of appreciation is almost exclusively a function of clinical and scientific progress — and the March 2026 Quarterly Report reveals a company that has delivered meaningful milestones across multiple programs simultaneously.

The Q3 FY2026 report covering the period ended 31 March 2026 details activity across three clinical programs: the CPACS Phase 1 trial assessing RC220 in cardioprotection alongside anticancer treatment, the HARNESS-1 Phase 1 trial for lung cancer, and preparatory work for the AML (acute myeloid leukaemia) program. When considered alongside the AACR presentation of new mechanistic data and the collaboration with Emory University, the quarter reflects a company in genuine operational momentum.

The Science Behind the Stock: Understanding RC220 and Bisantrene

Central to Racura's clinical thesis is RC220, a formulation of the active compound (E,E)-bisantrene. Bisantrene is not a new molecule — it has historical use in oncology — but Racura is developing it through novel clinical applications and a growing understanding of its mechanism of action. The most significant recent mechanistic discovery, presented at AACR 2026, demonstrated that bisantrene silences MYC gene expression by stabilising a G-quadruplex DNA structure located in the promoter region of the c-MYC oncogene.

This is scientifically significant because c-MYC is one of the most frequently mutated and overexpressed oncogenes in human cancers, implicated across a wide range of tumour types including breast, colon, lymphoma, and many others. A compound that can reliably suppress MYC expression through a structural DNA mechanism — rather than a conventional protein-binding approach — addresses a target that has historically been considered 'undruggable.' If this finding is borne out in clinical settings, it positions RC220 as potentially much more than a lung cancer drug, with applications spanning multiple oncology indications.

HARNESS-1: The Lung Cancer Trial Enters the Clinic

The first patient was recruited to the HARNESS-1 Phase 1 clinical trial on 31 March 2026 — a milestone that moved the lung cancer program from preclinical to clinical status. HARNESS-1 is assessing RC220 in combination with osimertinib (AstraZeneca's Tagrisso) in patients with EGFR-mutated non-small cell lung cancer (EGFRm NSCLC). The scientific rationale is compelling: while osimertinib is a highly effective first-line treatment for EGFRm NSCLC, the majority of patients develop resistance over time. The preclinical collaboration with Emory University, announced in January 2026 and led by internationally recognised researcher Professor Shi-Yong Sun, is specifically designed to study bisantrene in osimertinib-resistant models — supporting the clinical trial's aim of delaying or preventing that resistance.

The first participant was recruited by Principal Investigator Associate Professor Surein Arulananda and his team at Monash Health in Clayton, Victoria. The governance and ethics approvals — received in November 2025 and March 2026 respectively — were both obtained within a reasonable timeframe, suggesting no material regulatory obstacles to the trial's conduct. Phase 1 trials of this design are primarily focused on safety, tolerability, and pharmacokinetics, meaning near-term data readouts will centre on dosing and safety profiles rather than efficacy endpoints.

CPACS Trial: Cardioprotection Thesis Strengthened by New Blood Test

The CPACS (Cardioprotection and Anticancer Synergy) Phase 1 trial is assessing RC220's ability to protect the heart from the cardiotoxic effects of doxorubicin — a widely used chemotherapy agent associated with significant long-term cardiac damage. In February 2026, Racura announced the development of a new blood-based molecular test specifically designed to evaluate the cardioprotective effects of RC220 by quantifying its impact on molecular pathways linked to anthracycline cardiotoxicity.

The development of this biomarker test is clinically important because it provides an objective, early-stage measure of RC220's mechanism in patients — potentially enabling dose escalation and trial recruitment decisions to be made with greater precision. The first patient in Hong Kong was treated in March 2026 at Queen Mary Hospital, with Principal Investigator Dr Roland Ching-Yu Leung's team reporting no adverse events including no phlebitis following dosing. The third patient overall having been treated represents meaningful early-stage clinical progression.

Cash Position and Funding Runway: A Key Differentiator

One of the most practically important metrics for any pre-revenue biotech is its cash runway, and Racura's position is comparatively strong. The company held $19.38 million in cash and cash equivalents at 31 March 2026, with management stating this provides sufficient funding for all committed activities through CY2027. This is a meaningful statement for investors, as it removes the prospect of near-term dilutive Capital raisings as a valuation overhang for at least the next eighteen months.

In Q3 FY2026, total cash outflows were approximately $3.0 million, with more than 81% ($2.44 million) directed toward Research and Development and drug Manufacturing activities — reflecting a focused allocation of capital to clinical and scientific progress. Early conversion of Options provided an additional $1.44 million during the quarter, a small but meaningful inflow. If the quarterly Burn Rate is maintained at approximately $3 million, the current cash balance supports roughly six-plus quarters of operations — though clinical milestones that trigger increased site or manufacturing costs could accelerate spending.

Conclusion

Racura Oncology's near-doubling of share price over twelve months reflects genuine scientific and clinical progress rather than speculative momentum alone. The company has advanced three clinical programs, presented at a top-tier international oncology conference, established a collaboration with a globally recognised academic institution, and done so while maintaining a cash balance sufficient to fund operations through CY2027. The HARNESS-1 trial's first patient enrolment and the AACR presentation of MYC silencing data represent the two most significant value-creating milestones in the most recent period. For investors with a biotech risk appetite and an understanding of the binary nature of clinical trial outcomes, Racura's active pipeline and funded runway make it a company worthy of close attention over the coming twelve to eighteen months.